Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6CBJ

Crystal Structure of DH270.3 Fab in complex with Man9

6CBJ の概要
エントリーDOI10.2210/pdb6cbj/pdb
関連するPDBエントリー5TPL
分子名称DH270.3 Fab heavy chain, DH270.3 Fab light chain, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
機能のキーワードfab fragment, hiv-1, antibody, glycan, immune system
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数2
化学式量合計50529.78
構造登録者
Fera, D.,Harrison, S.C. (登録日: 2018-02-03, 公開日: 2018-02-21, 最終更新日: 2024-10-23)
主引用文献Fera, D.,Lee, M.S.,Wiehe, K.,Meyerhoff, R.R.,Piai, A.,Bonsignori, M.,Aussedat, B.,Walkowicz, W.E.,Ton, T.,Zhou, J.O.,Danishefsky, S.,Haynes, B.F.,Harrison, S.C.
HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.
Nat Commun, 9:1111-1111, 2018
Cited by
PubMed Abstract: HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and potential therapeutics. Here we use a synthetic V3-glycopeptide ("Man-V3") for structural studies of an HIV Env third variable loop (V3)-glycan directed, broadly neutralizing antibody (bnAb) lineage ("DH270"), to visualize the epitope on Env and to study how affinity maturation of the lineage proceeded. Unlike many previous V3 mimetics, Man-V3 encompasses two key features of the V3 region recognized by V3-glycan bnAbs-the conserved GDIR motif and the N332 glycan. In our structure of an antibody fragment of a lineage member, DH270.6, in complex with the V3 glycopeptide, the conformation of the antibody-bound glycopeptide conforms closely to that of the corresponding segment in an intact HIV-1 Env trimer. An additional structure identifies roles for two critical mutations in the development of breadth. The results suggest a strategy for use of a V3 glycopeptide as a vaccine immunogen.
PubMed: 29549260
DOI: 10.1038/s41467-018-03565-6
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.85 Å)
構造検証レポート
Validation report summary of 6cbj
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon